Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren in IgA Nephropathy
NCT00870493Phase 3Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Apr 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in IgA nephropathy (IgAN) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Change in the degree of proteinuria at 16 weeks. Started Apr 2009; status: completed.
02
Drugs
aliskiren
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT00870493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870493.